Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) major shareholder Proquest Investments Iv, L.P. sold 5,030 shares of Eagle Pharmaceuticals stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $75.39, for a total transaction of $379,211.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Proquest Investments Iv, L.P. also recently made the following trade(s):

  • On Wednesday, November 9th, Proquest Investments Iv, L.P. sold 153,830 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $79.29, for a total transaction of $12,197,180.70.
  • On Friday, November 4th, Proquest Investments Iv, L.P. sold 245,770 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $71.02, for a total transaction of $17,454,585.40.
  • On Friday, September 30th, Proquest Investments Iv, L.P. sold 22,100 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $70.06, for a total transaction of $1,548,326.00.
  • On Thursday, September 29th, Proquest Investments Iv, L.P. sold 77,900 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $70.04, for a total transaction of $5,456,116.00.
  • On Wednesday, September 21st, Proquest Investments Iv, L.P. sold 99,795 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $66.17, for a total transaction of $6,603,435.15.
  • On Thursday, September 8th, Proquest Investments Iv, L.P. sold 70,925 shares of Eagle Pharmaceuticals stock. The shares were sold at an average price of $62.50, for a total transaction of $4,432,812.50.
  • On Wednesday, August 24th, Proquest Investments Iv, L.P. sold 28,870 shares of Eagle Pharmaceuticals stock. The shares were sold at an average price of $63.00, for a total transaction of $1,818,810.00.
  • On Tuesday, August 16th, Proquest Investments Iv, L.P. sold 60,150 shares of Eagle Pharmaceuticals stock. The shares were sold at an average price of $61.67, for a total transaction of $3,709,450.50.
  • On Monday, August 15th, Proquest Investments Iv, L.P. sold 24,949 shares of Eagle Pharmaceuticals stock. The shares were sold at an average price of $60.77, for a total transaction of $1,516,150.73.
  • On Wednesday, August 17th, Proquest Investments Iv, L.P. sold 99,795 shares of Eagle Pharmaceuticals stock. The shares were sold at an average price of $61.36, for a total transaction of $6,123,421.20.

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) opened at 79.50 on Monday. Eagle Pharmaceuticals Inc. has a 1-year low of $33.02 and a 1-year high of $102.48. The firm has a 50-day moving average of $67.54 and a 200-day moving average of $53.70. The stock has a market cap of $1.23 billion, a PE ratio of 51.79 and a beta of 1.37.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Wednesday, November 9th. The specialty pharmaceutical company reported $0.73 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.12. Eagle Pharmaceuticals had a net margin of 20.06% and a return on equity of 25.63%. The firm had revenue of $37.80 million for the quarter, compared to analysts’ expectations of $41.04 million. During the same quarter in the prior year, the business earned ($0.65) EPS. The business’s quarterly revenue was up 563.2% on a year-over-year basis. Analysts expect that Eagle Pharmaceuticals Inc. will post $3.87 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Several institutional investors have recently modified their holdings of the company. ProShare Advisors LLC boosted its position in shares of Eagle Pharmaceuticals by 0.8% in the second quarter. ProShare Advisors LLC now owns 12,723 shares of the specialty pharmaceutical company’s stock valued at $494,000 after buying an additional 97 shares during the period. California State Teachers Retirement System boosted its position in shares of Eagle Pharmaceuticals by 1.1% in the third quarter. California State Teachers Retirement System now owns 18,765 shares of the specialty pharmaceutical company’s stock valued at $1,314,000 after buying an additional 200 shares during the period. Rhumbline Advisers boosted its position in shares of Eagle Pharmaceuticals by 3.3% in the second quarter. Rhumbline Advisers now owns 9,295 shares of the specialty pharmaceutical company’s stock valued at $361,000 after buying an additional 297 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Eagle Pharmaceuticals by 2.9% in the second quarter. PNC Financial Services Group Inc. now owns 12,578 shares of the specialty pharmaceutical company’s stock valued at $488,000 after buying an additional 349 shares during the period. Finally, Royal Bank of Canada boosted its position in shares of Eagle Pharmaceuticals by 3.5% in the second quarter. Royal Bank of Canada now owns 12,351 shares of the specialty pharmaceutical company’s stock valued at $479,000 after buying an additional 417 shares during the period.

Several analysts have recently issued reports on the stock. Piper Jaffray Cos. reissued a “buy” rating and issued a $91.00 price target on shares of Eagle Pharmaceuticals in a research report on Saturday, October 15th. Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $84.00 price target on the stock in a research report on Friday, November 4th. RBC Capital Markets reissued an “outperform” rating and issued a $93.00 price target (up previously from $80.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 3rd. Mizuho lowered their price target on shares of Eagle Pharmaceuticals from $65.00 to $62.00 and set a “buy” rating on the stock in a research report on Wednesday, October 26th. Finally, TheStreet raised shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Eagle Pharmaceuticals has an average rating of “Buy” and an average target price of $90.24.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

5 Day Chart for NASDAQ:EGRX

Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.